RCEL vs SPRO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
RCEL presents a high-risk profile characterized by a stable Piotroski F-Score (5/9) that masks severe underlying liquidity and solvency issues. The company exhibits negative shareholders' equity (Price/Book: -9.43) and a critical liquidity shortage with a current ratio of 0.57, indicating an inability to cover short-term obligations. Despite strong gross margins (82.13%) and bullish analyst targets, the fundamental trend is negative with shrinking revenue (-4.30%) and a consistent history of missing earnings estimates.
SPRO exhibits a critical divergence between its explosive revenue growth and its underlying financial health, evidenced by a weak Piotroski F-Score of 2/9. While the company maintains a strong current ratio (7.59) and low debt, the current price of $2.75 trades at a significant premium to both its Graham Number ($1.88) and Intrinsic Value ($1.05). This valuation gap, combined with aggressive insider selling by the CEO and COO and a bearish technical trend, suggests the recent 1-year price surge is unsustainable. The negative forward P/E further indicates an expectation of returning to losses despite recent revenue spikes.
Compare Another Pair
Related Comparisons
RCEL vs SPRO: Head-to-Head Comparison
This page compares AVITA Medical, Inc. (RCEL) and Spero Therapeutics, Inc. (SPRO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.